Hiroki Akiba

This study evaluates how site-specific PEG modification and PEG size affect trastuzumab's antibody functions, finding size-dependent reductions in ADCC activity and antigen/Fc receptor interactions.

This study develops a chemical method to enhance oxidative protein folding within PDIA6 condensates, showing up to 12-fold acceleration in vitro and improved insulin secretion in cells.

The paper converts an agonistic anti-TNFR2 biparatopic antibody into an antagonist by inserting peptide linkers into the hinge region, altering its immunocomplex formation.

This study develops biparatopic anti-CD30 antibodies by determining epitopes and analyzing their agonistic and antagonistic activities.